double top includes a solid major high as second top=SELL1->3 : we create a double top with the area above 1 and 3 being a
pressure zone pushing price down
2: this is the low created when sellers entered the first time
4: the is the low created when sellers entered the second time
3 : due to the fact that the sellers that originated from 3 created
Key facts today
Merck & Co. is raising $5 billion in bonds to fund its $10 billion acquisition of Verona Pharma, with Bank of America leading the financing through various notes and bonds.
Merck & Co. plans to invest $895 million to expand its animal health site in Kansas, part of a $9 billion U.S. investment by 2028, while managing potential tariff impacts.
Biocytogen Pharmaceuticals has entered into an agreement with Merck & Co. to advance the development of antibody-conjugated lipid-based delivery solutions.
1.15 USD
15.20 B USD
56.82 B USD
About Merck & Company, Inc.
Sector
Industry
CEO
Robert M. Davis
Website
Headquarters
Rahway
Founded
1891
ISIN
ARDEUT110277
FIGI
BBG000FT0R36
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Related stocks
Is Merck Ready for a Rebound?Fundamental Analysis
Financial Performance
Revenue Decline: Q2 revenue fell 2% year-over-year to $15.8 billion.
Earnings Drop: Adjusted earnings per share decreased by 7% to $2.13.
Key Product Challenges
Keytruda Competition: Facing increased competition for its top cancer drug, Keyt
Can Global Chaos Fuel Pharmaceutical Giants?Merck's remarkable growth trajectory demonstrates how a pharmaceutical leader can transform global uncertainties into strategic advantages. The company has masterfully navigated geopolitical tensions, including US-China trade disputes, by diversifying supply chains and establishing regionalized manu
MRK potentially enters the Wyckoff accumulation phase this week.The weekly chart points strongly towards a stock emerging from a prolonged Markdown Phase and potentially entering Accumulation (Phase C), with signs of strength appearing.
Merck is basically yelling 'buy me' across all timeframes, so I'm jumping into a long call
MRK - Retesting BreakoutAfter being in a downtrend for almost a year things finally look like they are starting to turn around for MRK.
Recently price broke the downwards sloping resistance and has retested that level as a new support level. We have also seen strength increasing on our daily RSI bringing some life back i
MRK Wave Analysis – 14 July 2025- MRK reversed from the support zone
- Likely to rise to resistance level 85.00
MRK recently reversed up from the support zone surrounding the long-term support level 73.45 (which has been reversing the price from the start of 2020, as can be seen from the weekly MRK chart below).
The upward rever
MRK Buying Opportunity!MRK is currently undervalued. The stock price dropped approximately 45% from June 25th of last year to May 15th of this year. At present, the price has bounced off a long-term weekly trendline that has been respected since 2009, indicating a strong rejection zone.
Additionally, on the daily timefra
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MRK3675698
Merck & Co., Inc. 5.85% 30-JUN-2039Yield to maturity
—
Maturity date
Jun 30, 2039
MRK3671638
Schering-Plough Corporation 6.55% 15-SEP-2037Yield to maturity
—
Maturity date
Sep 15, 2037
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050Yield to maturity
—
Maturity date
Jun 24, 2050
MRK5319197
Merck & Co., Inc. 2.9% 10-DEC-2061Yield to maturity
—
Maturity date
Dec 10, 2061
MRK5584756
Merck & Co., Inc. 5.15% 17-MAY-2063Yield to maturity
—
Maturity date
May 17, 2063
MRK3900816
Merck & Co., Inc. 3.6% 15-SEP-2042Yield to maturity
—
Maturity date
Sep 15, 2042
MRK.GJ
Merck & Co., Inc. FRN 06-FEB-2041Yield to maturity
—
Maturity date
Feb 6, 2041
MRK5584925
Merck & Co., Inc. 4.9% 17-MAY-2044Yield to maturity
—
Maturity date
May 17, 2044
MRK4806277
Merck & Co., Inc. 3.4% 07-MAR-2029Yield to maturity
—
Maturity date
Mar 7, 2029
MRK5584755
Merck & Co., Inc. 5.0% 17-MAY-2053Yield to maturity
—
Maturity date
May 17, 2053
MRK5584924
Merck & Co., Inc. 4.5% 17-MAY-2033Yield to maturity
—
Maturity date
May 17, 2033
See all MRKD bonds